Is cataract surgery the best way to lower IOP?

Article

Extraction of cataracts lowers intraocular pressure (IOP) to normal levels in glaucoma patients, and may in fact be a better treatment option than combined surgery, according to a study presented at this year's meeting of the Italian Society of Ophthalmology.

Extraction of cataracts lowers intraocular pressure (IOP) to normal levels in glaucoma patients, and may in fact be a better treatment option than combined surgery, according to data presented at this year's meeting of the Italian Society of Ophthalmology.

Richard L. Lindstrom, MD of Minnesota Eye Consultants, US conducted a retrospective review of 588 eyes undergoing cataract extraction with intraocular lens (IOL) implantation in patients with both glaucoma and cataract.

Dr Lindstrom observed IOP reduction in "most" cases. A mean decrease of 7 mmHg was observed in patients with IOP levels of 23–31 mmHg. Patients with higher preoperative IOP levels showed a greater post-surgical IOP reduction.

Dr Lindstrom concluded that the lens plays a more significant role in the development of glaucoma than had previously been acknowledged and that, therefore, except for in cases of severe glaucoma, cataract surgery alone is an appropriate treatment for lowering IOP.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.